1
|
McQuiston A, Yang J, Romero J, Bojjireddy N, McQuiston T, Sebastiano V, Turkoz M. Abstract 4108: Transient epigenetic reprogramming enhances T-cell proliferation and tumor clearance. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-4108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Manufacturing-induced differentiation and accelerated T-cell exhaustion prevent CAR-T therapies from reaching their full therapeutic potential and broader application in the treatment of cancer. To combat these inherent challenges, Turn Biotechnologies is developing its novel and proprietary mRNA-based technology, Epigenetic Reprogramming of Aging (ERATM), to i) preserve a less differentiated status; ii) diminish (or even eliminate) exhaustion; and iii) improve the cytotoxicity and efficacy of CAR-T cell cells. Prolonged CAR-T cell manufacturing process leads to a more differentiated and effector-like phenotype, which is susceptible to accelerated exhaustion in vivo. Unfortunately, clinical evidence suggests that less differentiated and stem-cell like CAR-T products have increased proliferative capacity, reduced exhaustion, and greater efficacy. Additionally, aging is known to compromise T-cell function, reducing chances of CAR-T therapy candidacy for older patients. These compounded effects of manufacturing and aging severely limit CAR-T cell functionality in terms of proliferation, perdurance, and cytotoxic capacity, as well as precluding wider patient access. Leveraging our previous work with other aged human cells, we hypothesized that the transient expression of ERATM factors could impact manufacturing of CAR-T cells by mitigating their differentiation, promoting T stem cell memory (Tscm) phenotype, reducing/eliminating exhaustion, and resetting the epigenetic clock in CAR-T cells. Here, we present preclinical data showing that ERATM treatment of T cells delivered using our proprietary eTurnaTM platform can restore youthful functionality, reducing exhaustion and effects of aging, improving their ability to fight cancer while safely maintaining cellular identity. ERATM -treated T cells have higher proliferation capacity and cytotoxicity upon tumor cell engagement in vitro compared to control cells. Treatment of ERATM -treated T-cells also increases the production of beneficial cytokines to support their survival and cytotoxic activity. Importantly, ERATM treatment preserves T-cell identity and T-cell repertoire, while avoiding unwanted hyperproliferation or clonal expansion. In murine models of hematological cancers, these effects of ERATM treatment on T-cells results in superior cancer cell killing and clearance. These benefits of ERATM technology to current CAR-T manufacturing processes have the potential to translate into the clinic as improved patient outcomes and survival with reduced side effects, thereby expanding patient access and enabling immunotherapies to serve as a first-in-line lifesaving solution.
Citation Format: Alec McQuiston, Junbao Yang, Jason Romero, Naveen Bojjireddy, Travis McQuiston, Vittorio Sebastiano, Mustafa Turkoz. Transient epigenetic reprogramming enhances T-cell proliferation and tumor clearance. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4108.
Collapse
Affiliation(s)
| | - Junbao Yang
- 1Turn Biotechnologies, Inc., Mountain View, CA
| | | | | | | | | | | |
Collapse
|
2
|
Cao Y, Bojjireddy N, Kim M, Li T, Zhai P, Nagarajan N, Sadoshima J, Palmiter RD, Tian R. Activation of γ2-AMPK Suppresses Ribosome Biogenesis and Protects Against Myocardial Ischemia/Reperfusion Injury. Circ Res 2017; 121:1182-1191. [PMID: 28835357 DOI: 10.1161/circresaha.117.311159] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/25/2017] [Revised: 08/17/2017] [Accepted: 08/23/2017] [Indexed: 11/16/2022]
Abstract
RATIONALE AMPK (AMP-activated protein kinase) is a heterotrimeric protein that plays an important role in energy homeostasis and cardioprotection. Two isoforms of each subunit are expressed in the heart, but the isoform-specific function of AMPK remains unclear. OBJECTIVE We sought to determine the role of γ2-AMPK in cardiac stress response using bioengineered cell lines and mouse models containing either isoform of the γ-subunit in the heart. METHODS AND RESULTS We found that γ2 but not γ1 or γ3 subunit translocated into nucleus on AMPK activation. Nuclear accumulation of AMPK complexes containing γ2-subunit phosphorylated and inactivated RNA Pol I (polymerase I)-associated transcription factor TIF-IA at Ser-635, precluding the assembly of transcription initiation complexes for rDNA. The subsequent downregulation of pre-rRNA level led to attenuated endoplasmic reticulum (ER) stress and cell death. Deleting γ2-AMPK led to increases in pre-rRNA level, ER stress markers, and cell death during glucose deprivation, which could be rescued by inhibition of rRNA processing or ER stress. To study the function of γ2-AMPK in the heart, we generated a mouse model with cardiac-specific deletion of γ2-AMPK (cardiac knockout [cKO]). Although the total AMPK activity was unaltered in cKO hearts because of upregulation of γ1-AMPK, the lack of γ2-AMPK sensitizes the heart to myocardial ischemia/reperfusion injury. The cKO failed to suppress pre-rRNA level during ischemia/reperfusion and showed a greater infarct size. Conversely, cardiac-specific overexpression of γ2-AMPK decreased ribosome biosynthesis and ER stress during ischemia/reperfusion insult, and the infarct size was reduced. CONCLUSIONS The γ2-AMPK translocates into the nucleus to suppress pre-rRNA transcription and ribosome biosynthesis during stress, thus ameliorating ER stress and cell death. Increased γ2-AMPK activity is required to protect against ischemia/reperfusion injury. Our study reveals an isoform-specific function of γ2-AMPK in modulating ribosome biosynthesis, cell survival, and cardioprotection.
Collapse
Affiliation(s)
- Yang Cao
- From the Department of Anesthesiology and Pain Medicine, Mitochondria and Metabolism Center (Y.C., N.B., M.K., T.L., R.T.) and Department of Biochemistry (R.D.P.), University of Washington, Seattle; Department of Cell Biology and Molecular Medicine, Rutgers New Jersey Medical School, Newark (P.Z., N.N., J.S.); and Howard Hughes Medical Institute, Seattle, WA (R.D.P.)
| | - Naveen Bojjireddy
- From the Department of Anesthesiology and Pain Medicine, Mitochondria and Metabolism Center (Y.C., N.B., M.K., T.L., R.T.) and Department of Biochemistry (R.D.P.), University of Washington, Seattle; Department of Cell Biology and Molecular Medicine, Rutgers New Jersey Medical School, Newark (P.Z., N.N., J.S.); and Howard Hughes Medical Institute, Seattle, WA (R.D.P.)
| | - Maengjo Kim
- From the Department of Anesthesiology and Pain Medicine, Mitochondria and Metabolism Center (Y.C., N.B., M.K., T.L., R.T.) and Department of Biochemistry (R.D.P.), University of Washington, Seattle; Department of Cell Biology and Molecular Medicine, Rutgers New Jersey Medical School, Newark (P.Z., N.N., J.S.); and Howard Hughes Medical Institute, Seattle, WA (R.D.P.)
| | - Tao Li
- From the Department of Anesthesiology and Pain Medicine, Mitochondria and Metabolism Center (Y.C., N.B., M.K., T.L., R.T.) and Department of Biochemistry (R.D.P.), University of Washington, Seattle; Department of Cell Biology and Molecular Medicine, Rutgers New Jersey Medical School, Newark (P.Z., N.N., J.S.); and Howard Hughes Medical Institute, Seattle, WA (R.D.P.)
| | - Peiyong Zhai
- From the Department of Anesthesiology and Pain Medicine, Mitochondria and Metabolism Center (Y.C., N.B., M.K., T.L., R.T.) and Department of Biochemistry (R.D.P.), University of Washington, Seattle; Department of Cell Biology and Molecular Medicine, Rutgers New Jersey Medical School, Newark (P.Z., N.N., J.S.); and Howard Hughes Medical Institute, Seattle, WA (R.D.P.)
| | - Narayani Nagarajan
- From the Department of Anesthesiology and Pain Medicine, Mitochondria and Metabolism Center (Y.C., N.B., M.K., T.L., R.T.) and Department of Biochemistry (R.D.P.), University of Washington, Seattle; Department of Cell Biology and Molecular Medicine, Rutgers New Jersey Medical School, Newark (P.Z., N.N., J.S.); and Howard Hughes Medical Institute, Seattle, WA (R.D.P.)
| | - Junichi Sadoshima
- From the Department of Anesthesiology and Pain Medicine, Mitochondria and Metabolism Center (Y.C., N.B., M.K., T.L., R.T.) and Department of Biochemistry (R.D.P.), University of Washington, Seattle; Department of Cell Biology and Molecular Medicine, Rutgers New Jersey Medical School, Newark (P.Z., N.N., J.S.); and Howard Hughes Medical Institute, Seattle, WA (R.D.P.)
| | - Richard D Palmiter
- From the Department of Anesthesiology and Pain Medicine, Mitochondria and Metabolism Center (Y.C., N.B., M.K., T.L., R.T.) and Department of Biochemistry (R.D.P.), University of Washington, Seattle; Department of Cell Biology and Molecular Medicine, Rutgers New Jersey Medical School, Newark (P.Z., N.N., J.S.); and Howard Hughes Medical Institute, Seattle, WA (R.D.P.)
| | - Rong Tian
- From the Department of Anesthesiology and Pain Medicine, Mitochondria and Metabolism Center (Y.C., N.B., M.K., T.L., R.T.) and Department of Biochemistry (R.D.P.), University of Washington, Seattle; Department of Cell Biology and Molecular Medicine, Rutgers New Jersey Medical School, Newark (P.Z., N.N., J.S.); and Howard Hughes Medical Institute, Seattle, WA (R.D.P.).
| |
Collapse
|
3
|
Bojjireddy N, Guzman-Hernandez ML, Reinhard NR, Jovic M, Balla T. EFR3s are palmitoylated plasma membrane proteins that control responsiveness to G-protein-coupled receptors. J Cell Sci 2014; 128:118-28. [PMID: 25380825 DOI: 10.1242/jcs.157495] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
The yeast Efr3p protein is a main regulator of the Stt4p phosphatidylinositol 4-kinase at contact sites between the endoplasmic reticulum and the plasma membrane. A mutation in its fly homologue Rbo, leads to diminished light responses in the eye attributed to progressively impaired PLC signaling. Here, we find that Efr3s plays a role in maintaining responsiveness to the type-I angiotensin II (AngII) receptors. siRNA-mediated depletion of EFR3A and EFR3B impaired the sustained phase of cytosolic Ca(2+) response to high concentration of AngII in HEK293 cells that express wild type but not truncated AGTR1 (AT1a receptor), missing the phosphorylation sites. Efr3 depletion had minimal effect on the recovery of plasma membrane phosphoinositides during stimulation, and AT1 receptors still underwent ligand-induced internalization. A higher level of basal receptor phosphorylation and a larger response was observed after stimulation. Moreover, Gq activation more rapidly desensitized after AngII stimulation in Efr3 downregulated cells. A similar but less pronounced effect of EFR3 depletion was observed on the desensitization of the cAMP response after stimulation with isoproterenol. These data suggest that mammalian Efr3s contribute to the control of the phosphorylation state and, hence, desensitization of AT1a receptors, and could affect responsiveness of G-protein-coupled receptors in higher eukaryotes.
Collapse
Affiliation(s)
- Naveen Bojjireddy
- Section on Molecular Signal Transduction, Program for Developmental Neuroscience, Eunice Kennedy Shriver NICHD, National Institutes of Health, Bethesda, MD 20892, USA
| | - Maria Luisa Guzman-Hernandez
- Section on Molecular Signal Transduction, Program for Developmental Neuroscience, Eunice Kennedy Shriver NICHD, National Institutes of Health, Bethesda, MD 20892, USA
| | - Nathalie Renée Reinhard
- Swammerdam Institute for Life Sciences, University of Amsterdam, 1012 WX Amsterdam, The Netherlands
| | - Marko Jovic
- Section on Molecular Signal Transduction, Program for Developmental Neuroscience, Eunice Kennedy Shriver NICHD, National Institutes of Health, Bethesda, MD 20892, USA
| | - Tamas Balla
- Section on Molecular Signal Transduction, Program for Developmental Neuroscience, Eunice Kennedy Shriver NICHD, National Institutes of Health, Bethesda, MD 20892, USA
| |
Collapse
|
5
|
Bojjireddy N, Botyanszki J, Hammond G, Creech D, Peterson R, Kemp DC, Snead M, Brown R, Morrison A, Wilson S, Harrison S, Moore C, Balla T. Pharmacological and genetic targeting of the PI4KA enzyme reveals its important role in maintaining plasma membrane phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate levels. J Biol Chem 2014; 289:6120-32. [PMID: 24415756 DOI: 10.1074/jbc.m113.531426] [Citation(s) in RCA: 120] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Phosphatidylinositol 4-kinase type IIIα (PI4KA) is a host factor essential for hepatitis C virus replication and hence is a target for drug development. PI4KA has also been linked to endoplasmic reticulum exit sites and generation of plasma membrane phosphoinositides. Here, we developed highly specific and potent inhibitors of PI4KA and conditional knock-out mice to study the importance of this enzyme in vitro and in vivo. Our studies showed that PI4KA is essential for the maintenance of plasma membrane phosphatidylinositol 4,5-bisphosphate pools but only during strong stimulation of receptors coupled to phospholipase C activation. Pharmacological blockade of PI4KA in adult animals leads to sudden death closely correlating with the drug's ability to induce phosphatidylinositol 4,5-bisphosphate depletion after agonist stimulation. Genetic inactivation of PI4KA also leads to death; however, the cause in this case is due to severe intestinal necrosis. These studies highlight the risks of targeting PI4KA as an anti-hepatitis C virus strategy and also point to important distinctions between genetic and pharmacological studies when selecting host factors as putative therapeutic targets.
Collapse
Affiliation(s)
- Naveen Bojjireddy
- From the Section on Molecular Signal Transduction, Program for Developmental Neuroscience, Eunice Kennedy Shriver NICHD, National Institutes of Health, Bethesda, Maryland 20892 and
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Bojjireddy N, Sinha RK, Subrahmanyam G. Fyn kinase regulates type II PtdIns 4-kinases in RBL 2H3 cells. Mol Cell Biochem 2013; 387:63-70. [PMID: 24173619 DOI: 10.1007/s11010-013-1871-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2013] [Accepted: 10/18/2013] [Indexed: 10/26/2022]
Abstract
Type II phosphatidylinositol 4-kinases are implicated in FcεRI-mediated signaling cascades leading to release of inflammatory molecules. Cross-linking of FcεRI on RBL 2H3 cells results in protein tyrosine phosphorylation and activation of type II PtdIns 4-kinase activity. Protein tyrosine kinase(s) that phosphorylate type II PtdIns 4-kinase(s) in RBL 2H3 cells remains elusive and is being addressed in this manuscript. Anti-Fyn kinase antibodies co-immunoprecipitated type II PtdIns 4-kinase activity from FcεRI cross-linked RBL 2H3 cells. In reciprocal assays, His-tagged types II PtdIns 4-kinases were shown to pull down Fyn kinase. Further, anti-Fyn immunoprecipitates were shown to phosphorylate type II PtdIns 4-kinase α and β in in vitro assays. Pull down studies with GST-Fyn-SH2 and GST-Fyn-SH3 domains showed that type II PtdIns 4-kinases associate with Fyn-SH2 domain. Knockdown of Fyn kinase in RBL 2H3 cells abrogated activation of type II PtdIns 4-kinase activity in response to FcεRI cross-linking and type II PtdIns 4-kinase activity in anti-phosphotyrosine immunoprecipitates. Knockdown of Fyn kinase was also strongly correlated with a reduction in β-hexosaminidase release in response to FcεRI cross-linking. These results suggest that type II PtdIns 4-kinases act downstream of Fyn kinase in FcεRI signaling cascades and are regulated by Fyn kinase.
Collapse
Affiliation(s)
- Naveen Bojjireddy
- Department of Biosciences and Bioengineering, Wadhwani Research Centre for Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai, 400076, India,
| | | | | |
Collapse
|
9
|
Sinha RK, Patel RY, Bojjireddy N, Datta A, Subrahmanyam G. Epigallocatechin gallate (EGCG) inhibits type II phosphatidylinositol 4-kinases: a key component in pathways of phosphoinositide turnover. Arch Biochem Biophys 2011; 516:45-51. [PMID: 21964243 DOI: 10.1016/j.abb.2011.09.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2011] [Revised: 09/11/2011] [Accepted: 09/14/2011] [Indexed: 11/28/2022]
Abstract
Type II phosphatidylinositol (PtdIns) 4-kinases produce PtdIns 4-phosphate, an early key signaling molecule in phosphatidylinositol cycle, which is indispensable for T cell activation. Type II PtdIns 4-kinase alpha and beta have similar biochemical properties. To distinguish these isoforms Epigallocatechin gallate (EGCG) has been evaluated as a specific inhibitor. EGCG is the major active catechin in green tea having anti-inflammatory, antiatherogenic and cancer chemopreventive properties. The precise mechanism of actions and molecular targets of EGCG in early signaling cascades are not well understood. In the present study, we have shown that EGCG inhibits type II PtdIns 4-kinases (α and β isoforms) and PtdIns 3-kinase activity in vitro. EGCG directly bind to both alpha and beta isoforms of type II PtdIns 4-kinases with a Kd of 2.62 μM and 1.02 μM, respectively. Type II PtdIns 4-kinase-EGCG complex have different binding pattern at its excited state. Both isoforms showed significant change in helicity upon binding with EGCG. EGCG modulates its effect by interacting with ATP binding pocket; the residues likely to be involved in EGCG binding were predicted by Autodock. Our findings suggest that EGCG inhibits two isoforms and could be a key to regulate T cell activation.
Collapse
Affiliation(s)
- Ranjeet K Sinha
- Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai, Maharashtra, India.
| | | | | | | | | |
Collapse
|
10
|
Tai AW, Bojjireddy N, Balla T. A homogeneous and nonisotopic assay for phosphatidylinositol 4-kinases. Anal Biochem 2011; 417:97-102. [PMID: 21704602 DOI: 10.1016/j.ab.2011.05.046] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2011] [Revised: 05/25/2011] [Accepted: 05/31/2011] [Indexed: 11/25/2022]
Abstract
Phosphatidylinositol 4-kinases (PI 4-kinases) catalyze the conversion of phosphatidylinositol to phosphatidylinositol 4-phosphate (PtdIns4P). The four known mammalian PI 4-kinases, PI4KA, PI4KB, PI4K2A, and PI4K2B have roles in intracellular lipid and protein trafficking. PI4KA and PI4KB also assist in the replication of several positive-sense RNA viruses. The identification of selective inhibitors of these kinases would be facilitated by assays suitable for high-throughput screening. We describe a homogeneous and nonisotopic assay for PI 4-kinase activity based on the bioluminescent detection of the ADP produced by kinase reactions. We have evaluated this assay with known nonselective inhibitors of PI 4-kinases and show that it performs similar to radiometric assay formats previously described in the literature. In addition, this assay generates Z-factor values of >0.7 for PI4KA in a 384-well format, demonstrating its suitability for high-throughput screening applications.
Collapse
Affiliation(s)
- Andrew W Tai
- Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48105, USA.
| | | | | |
Collapse
|